Yazar "Sezgin, C." seçeneğine göre listele
Listeleniyor 1 - 14 / 14
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Apoptosis-mediated Cytotoxic Effects of Ibandronic Acid on Hormone- and Drug-refractory Prostate Cancer Cells and Human Breast Cancer Cells(Field House Publishing Llp, 2010) Kucukzeybek, Y.; Gorumlu, G.; Cengiz, E.; Karabulut, B.; Sezgin, C.; Atmaca, H.; Sanli, U. A.; Uzunoglu, S.; Uslu, R.Over 80% of patients with advanced breast and prostate cancer ultimately develop bone metastases. Ibandronic acid has proven efficacy for treatment of bone metastasis secondary to breast cancer. This study was designed to investigate the cytotoxic and apoptotic effects of ibandronic acid on hormone- and drug-refractory prostate carcinoma DU-145 and human breast cancer MCF-7 cell lines. Cytotoxicity was evaluated using an XTT cell proliferation kit, and apoptosis was assessed by enzyme-linked immunosorbent assay (histone-DNA fragmentation) and measurement of caspase 3/7 activity. With increasing concentrations of ibandronic acid there was a dose- and time-dependent decrease in cell numbers. MCF-7 cells were more resistant than DU-145 cells (half maximal inhibitory concentrations of 122 and 90 mu M, respectively). Ibandronic acid induced apoptosis in both cell lines. The study showed an apoptosis-mediated cytotoxic effect for ibandronic acid (in addition to the already known osteoclast inhibiting effect) in breast cancer patients with bone metastases; which was also observed in prostate cancer cells. Further clinical studies involving breast and prostate cancer patients with bone metastases are warranted to confirm these findings.Öğe The association between sociodemographic parameters and the use of complementary interventions in patients with cancer in Turkey: A Turkish Oncology Group study.(Amer Soc Clinical Oncology, 2011) Turhal, N. S.; Kilickap, S.; Yalcin, S.; Sezgin, C.; Yamac, D.; Akbulut, H.; Ozyilkan, O.; Ozdemir, F.; Cabuk, D.; Sevinc, A.Öğe Bilateral Krukenberg tumor in a 16-week pregnant woman(I R O G Canada, Inc, 2014) Genc, M.; Genc, B.; Solak, A.; Gur, E.; Sezgin, C.The authors present the case of a G2P1001 who presented in 16-week gestation with bilateral Krukenberg tumor, abdominal pain, and iterative vomiting episodes. Although a few cases of Krukenberg tumor in pregnant women have been reported, no case reports asymptomatic and free of disease at 18 months were found in the English literature. Early detection followed by surgery and chemotherapy during pregnancy could possibly result in a favorable outcome in such patients.Öğe Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).(Amer Assoc Cancer Research, 2012) Abulkhair, O.; Uslu, R.; Sezgin, C.; Bueyuekberber, S.; Darwish, T.; Isikdogan, A.; Gumus, M.; Dane, F.; Sevinc, A.; Halawani, H.; Uncu, D.; Marrero, N.; Tobler, J.; Soares, C.; Landis, S.; Moraes, E.; Gidekel, R.; Santillana, S.; Nunez, P.; Cagnolati, S.; Rodriguez, J. G.Öğe Co-encapsulation of curcumin and piperin in zein-chitosane nanocapsules by electrospray(Wiley-Blackwell, 2016) Ustundag, M.; Baspinar, Y.; Bayraktar, O.; Sezgin, C.Öğe Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer(Imprimatur Publications, 2013) Cakar, B.; Varol, U.; Junushova, B.; Muslu, U.; Oner, P. Gursoy; Surmeli, Z. Gokhan; Cirak, Y.; Karaca, B.; Sezgin, C.; Karabulut, B.; Uslu, R.Purpose: This study aimed at comparing the disease-free survival (DFS) in high-risk TNM stage II colon cancer patients who had been subjected to adjuvant chemotherapy and TNM low-risk stage II patients who did not receive chemotherapy. Methods: : We retrospectively reviewed the medical records of stage II colon cancer patients between January 2006 and December 2011. High-risk patients were defined those with any colonic obstruction/perforation, mucinous histology, inadequate lymph node sampling, T4 disease, lymphatic/vascular or perineural invasion, preoperatively elevated carcinoembryonic antigen (CEA) and high-grade tumor. All patients with high-risk features received adjuvant chemotherapy. Results: There were 42 patients in the high-risk treatment group and 21 patients in the non-treatment (observation) group. There were no significant differences in terms of gender, tumor size, tumor localization, or the number of excised lymph nodes between the groups. The median follow-up time was 33.9 months in the treatment group and 29.3 months in the non-treatment group. Recurrence developed in 4 patients (6.3%), 3 of which were in the treatment group. DFS in both groups was statistically similar. Conclusion: Adjuvant chemotherapy in the high-risk patients resulted in similar DFS as that in the low-risk patients. Although the role of adjuvant chemotherapy for stage II colon cancer is unclear, it is rational to offer adjuvant chemotherapy to patients with high-risk stage II colon cancer.Öğe FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) POLYMORPHISM STATUS OF TURKISH BREAST CANCER PATIENTS(Oxford Univ Press, 2010) Uslu, R.; Karaca, B.; Atmaca, H.; Kisim, A.; Cakar, B.; Karabulut, B.; Sezgin, C.; Uzunoglu, S.Öğe The Imaging Performance of 89Zr in TOF PET/CT system(Springer, 2021) Parlak, Y.; Goksoy, D.; Sezgin, C.; Medine, I.; Gumuser, G.; Aras, O.; Sayit, E.[No Abstract Available]Öğe Investigation of the Radiolabelling Potential of the Aurora A Kinase Inhibitor Alisertib with Iodine-123 [123I](Springer, 2023) Uygur, E.; Sezgin, C.; Akdag, B. Y.; Ozbey, T.; Parlak, Y.; Karatay, K. B.; Gumuser, F. G.[No abstract available]Öğe Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.(Amer Soc Clinical Oncology, 2011) Icli, F.; Altundag, K.; Coskun, U.; Paydas, S.; Basaran, G.; Saip, P.; Dogu, G. G.; Eralp, Y.; Uslu, R.; Sevinc, A.; Onur, H.; Mandel, N. M.; Sezgin, C.; Altinbas, M.; Guler, N.; Isikdogan, A.; Gokmen, E.; Uygun, K.; Ustuner, Z.; Yaren, A.Öğe A potent enantiomer of gossypol, AT-101: Screening of anti-angiogenic protein targets in glioblastoma multiforme cells(Elsevier Sci Ltd, 2013) Surmeli, Z.; Bozkurt, E.; Karaca, B.; Karabulut, B.; Sezgin, C.; Sanli, U. A.; Uslu, R.Öğe Radiolabeling fingolimod with technetium-99 m and evaluating its biological affinity by in vitro method(Springer Science and Business Media B.V., 2023) Uygur, E.; Parlak, Y.; Karatay, K.B.; Sezgin, C.; Gümüşer, F.G.; Biber, Müftüler, F.Z.Fingolimod (FTY-720) is the first oral medication approved by the food and drug administration (FDA) for the treatment of multiple sclerosis. It acts on the central nervous system by crossing the blood–brain barrier and binding to sphingosine-1-phosphate receptors (S1PRs). FTY-720 protects against neural damage caused by mitochondrial dysfunction and cytotoxicity by modulating S1PR1. In this study, FTY-720 was radiolabeled with technetium-99 m [99mTc]Tc and the biological affinity of [99mTc]Tc-FTY-720 was assessed using in vitro methods. The radiochemical yield and stability of [99mTc]Tc-FTY-720 was over 95% during 4 h. [99mTc]Tc-FTY-720 showed uptake on the SH-SY5Y cell line. © 2023, Akadémiai Kiadó, Budapest, Hungary.Öğe Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease(Zerbinis Medical Publ, 2013) Varol, U.; Cirak, Y.; Cakar, B.; Karaca, B.; Sezgin, C.; Uslu, R.; Karabulut, B.Purpose: Exposure to all active agents may be more important than specific sequence of drug administration in the treatment of patients with metastatic colorectal cancer (mCRC). The purpose of this study was to evaluate the overall survival (OS) of mCRC patients who were treated with all 5 major therapeutic agents used in this malignancy. Methods: We retrospectively reviewed the medical records of 395 mCRC patients referred to our clinic. The study included patients who received 5-fluorouracil (5-FU)-, irinotecan- or oxaliplatin-based chemotherapy and at least 3 cycles of bevacizumab and 4 weeks of cetuximab sequentially in various combinations. Results: Forty mCRC patients received the 5 major therapeutic agents effectively and sequentially, and their mean OS was 26.43 +/- 2.04 months. The 3- and 4- year OS survival rates were 26.7% and 16.7%, respectively. When survival analysis was limited to the metastatic patients with at least 6 cycles of bevacizumab therapy in addition to standard duration of other chemotherapeutic agents (N=33), the mean OS was 26.7 +/- 2.38 months. With a further survival analysis limited to metastatic patients who were treated with at least both 6 cycles of bevacizumab and 8 weeks of cetuximab in addition to other therapies (N=17), the mean OS was 44.8 +/- 11.03 months. Conclusion: This study demonstrated that in mCRC patients there may be a significant survival advantage if an adequate tumor response was achieved with all major therapeutic agents. Therefore, we believe that we should treat our patients with the 5 major therapeutic drugs as effectively as possible.Öğe SYNERGISTIC CYTOTOXIC AND APOPTOTIC EFFECT BY AT-101 AND CISPLATIN COMBINATION THROUGH DNA METHYLTRANSFERASE AND HISTONE DEACETYLASE ENZYMES IN HUMAN OVARIAN CANCER CELL LINES(Oxford Univ Press, 2010) Karaca, B.; Atmaca, H.; Kisim, A.; Muslu, U.; Karabulut, B.; Sezgin, C.; Uzunoglu, S.; Uslu, R.